{"id":"W4417009527","doi":"10.1182/blood-2025-4079","title":"Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; Juravinski Cancer Centre","funders":"","keywords":"Multiple myeloma; Chimeric antigen receptor; Clinical trial; Phases of clinical research; Carfilzomib; Bortezomib; Antigen; Overall survival","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002267618,0.001261209,0.001633615,0.0003842712,0.0004499521,0.001259697,0.001131589,0.00160879,0.006566694],"category_scores_gemma":[0.0009248467,0.0004509513,0.001427032,0.0003672347,0.0008467372,0.001026117,0.0004100759,0.003714634,0.001292078],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007478626,"about_ca_system_score_gemma":0.001113246,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008710382,"about_ca_topic_score_gemma":0.002625551,"domain_scores_codex":[0.9993981,0.000335121,0.00002252808,0.00008980066,0.00004964885,0.000104735],"domain_scores_gemma":[0.9992673,0.000106603,0.0001322128,0.00006279501,0.00006613563,0.0003649528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7921891,0.04334862,0.006374694,0.001444594,0.002498794,0.000295496,0.0003225744,0.002110773,0.02831807,0.0005507444,0.008495041,0.1140515],"study_design_scores_gemma":[0.7777473,0.206604,0.007888854,0.00005452823,0.0003783981,0.0002134036,0.00005295809,0.0009820067,0.001629013,0.0002459943,0.004174892,0.00002869134],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9749511,0.00734282,0.001214378,0.002131534,0.0003691554,0.004301567,0.004332999,0.0003659551,0.004990475],"genre_scores_gemma":[0.977699,0.002715934,0.002216181,0.002561206,0.0002757749,0.003204888,0.004438277,0.00005656846,0.006832146],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006566694,"threshold_uncertainty_score":0.02196783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01657940779593589,"score_gpt":0.3164352646403779,"score_spread":0.299855856844442,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}